• Je něco špatně v tomto záznamu ?

The prognostic significance of periprocedural infarction in the era of potent antithrombotic therapy. The PRAGUE-18 substudy

J. Dusek, Z. Motovska, O. Hlinomaz, R. Miklik, M. Hromadka, I. Varvarovsky, J. Jarkovsky, F. Tousek, B. Majtan, S. Simek, M. Branny, J. Mrozek, P. Widimsky, Prague-18 Study Group

. 2020 ; 319 (-) : 1-6. [pub] 20200704

Jazyk angličtina Země Nizozemsko

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc21019828

BACKGROUND: The prognostic significance of periprocedural myocardial infarction (MI) remains controversial. METHODS AND RESULTS: The study aims to investigate the incidence of periprocedural MI in the era of high sensitivity diagnostic markers and intense antithrombotics, and its impact on early outcomes of patients with acute MI treated with primary angioplasty (pPCI). Data from the PRAGUE-18 (prasugrel versus ticagrelor in pPCI) study were analyzed. The primary net-clinical endpoint (EP) included death, spontaneous MI, stroke, severe bleeding, and revascularization at day 7. The key secondary efficacy EP included cardiovascular death, spontaneous MI, and stroke within 30 days. The incidence of peri-pPCI MI was 2.3% (N = 28) in 1230 study patients. The net-clinical EP occurred in 10.7% of patients with, and in 3.6% of patients without, peri-pPCI MI (HR 2.92; 95% CI 0.91-9.38; P = 0.059). The key efficacy EP was 10.7% and 3.2%, respectively (HR 3.44; 95% CI 1.06-11.13; P = 0.028). Patients with periprocedural MI were at a higher risk of spontaneous MI (HR 6.19; 95% CI 1.41-27.24; P = 0.006) and stent thrombosis (HR 10.77; 95% CI 2.29-50.70; P = 0.003) within 30 days. Age, hyperlipidemia, multi-vessel disease, post-procedural TIMI <3, pPCI on circumflex coronary artery, and periprocedural GP IIb/IIIa inhibitor were independent predictors of peri-pPCI MI. CONCLUSIONS: In the era of intense antithrombotic therapy, the occurrence of peri-pPCI MI is despite highly sensitive diagnostic markers a rare complication, and is associated with an increased risk of early reinfarction and stent thrombosis.

000      
00000naa a2200000 a 4500
001      
bmc21019828
003      
CZ-PrNML
005      
20210830101429.0
007      
ta
008      
210728s2020 ne f 000 0|eng||
009      
AR
024    7_
$a 10.1016/j.ijcard.2020.06.067 $2 doi
035    __
$a (PubMed)32634499
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a ne
100    1_
$a Dusek, Jaroslav $u Department of Cardiovascular Medicine I, University Hospital Hradec Kralove, Czech Republic
245    14
$a The prognostic significance of periprocedural infarction in the era of potent antithrombotic therapy. The PRAGUE-18 substudy / $c J. Dusek, Z. Motovska, O. Hlinomaz, R. Miklik, M. Hromadka, I. Varvarovsky, J. Jarkovsky, F. Tousek, B. Majtan, S. Simek, M. Branny, J. Mrozek, P. Widimsky, Prague-18 Study Group
520    9_
$a BACKGROUND: The prognostic significance of periprocedural myocardial infarction (MI) remains controversial. METHODS AND RESULTS: The study aims to investigate the incidence of periprocedural MI in the era of high sensitivity diagnostic markers and intense antithrombotics, and its impact on early outcomes of patients with acute MI treated with primary angioplasty (pPCI). Data from the PRAGUE-18 (prasugrel versus ticagrelor in pPCI) study were analyzed. The primary net-clinical endpoint (EP) included death, spontaneous MI, stroke, severe bleeding, and revascularization at day 7. The key secondary efficacy EP included cardiovascular death, spontaneous MI, and stroke within 30 days. The incidence of peri-pPCI MI was 2.3% (N = 28) in 1230 study patients. The net-clinical EP occurred in 10.7% of patients with, and in 3.6% of patients without, peri-pPCI MI (HR 2.92; 95% CI 0.91-9.38; P = 0.059). The key efficacy EP was 10.7% and 3.2%, respectively (HR 3.44; 95% CI 1.06-11.13; P = 0.028). Patients with periprocedural MI were at a higher risk of spontaneous MI (HR 6.19; 95% CI 1.41-27.24; P = 0.006) and stent thrombosis (HR 10.77; 95% CI 2.29-50.70; P = 0.003) within 30 days. Age, hyperlipidemia, multi-vessel disease, post-procedural TIMI <3, pPCI on circumflex coronary artery, and periprocedural GP IIb/IIIa inhibitor were independent predictors of peri-pPCI MI. CONCLUSIONS: In the era of intense antithrombotic therapy, the occurrence of peri-pPCI MI is despite highly sensitive diagnostic markers a rare complication, and is associated with an increased risk of early reinfarction and stent thrombosis.
650    _2
$a fibrinolytika $x škodlivé účinky $x terapeutické užití $7 D005343
650    _2
$a lidé $7 D006801
650    _2
$a koronární angioplastika $7 D062645
650    _2
$a inhibitory agregace trombocytů $7 D010975
650    _2
$a prasugrel hydrochlorid $7 D000068799
650    _2
$a prognóza $7 D011379
650    _2
$a rizikové faktory $7 D012307
650    _2
$a výsledek terapie $7 D016896
655    _2
$a časopisecké články $7 D016428
700    1_
$a Motovska, Zuzana $u Cardiocenter, Third Faculty of Medicine, Charles University and University Hospital Kralovske Vinohrady, Prague, Czech Republic. Electronic address: zuzana.motovska@fnkv.cz
700    1_
$a Hlinomaz, Ota $u First Department of Internal Medicine - Cardioangiology, ICRC, Faculty of Medicine of Masaryk University and St. Anne's University Hospital, Brno, Czech Republic
700    1_
$a Miklik, Roman $u Department of Internal Medicine and Cardiology, Faculty of Medicine of Masaryk University and University Hospital Brno, Brno, Czech Republic
700    1_
$a Hromadka, Milan $u Department of Cardiology, University Hospital and Faculty of Medicine in Pilsen, Charles University, Prague, Czech Republic
700    1_
$a Varvarovsky, Ivo $u Cardiology Centre AGEL, Pardubice, Czech Republic
700    1_
$a Jarkovsky, Jiri $u Institute of Biostatistics and Analyses at the Faculty of Medicine and the Faculty of Science of the Masaryk University, Brno, Czech Republic
700    1_
$a Tousek, Frantisek $u Cardiocenter - Department of Cardiology, Regional Hospital, Ceske Budejovice, Czech Republic
700    1_
$a Majtan, Bohumil $u Cardiocenter, Regional Hospital, Karlovy Vary, Czech Republic
700    1_
$a Simek, Stanislav $u 2nd Department of Medicine - Department of Cardiovascular Medicine, First Faculty of Medicine, Charles University in Prague and General University Hospital in Prague, Prague, Czech Republic
700    1_
$a Branny, Marian $u AGEL Research and Training Institute - Trinec Branch, Cardiovascular Center, Podlesi Hospital, Trinec, Czech Republic
700    1_
$a Mrozek, Jan $u Cardiovascular Department, University Hospital Ostrava, Ostrava, Czech Republic
700    1_
$a Widimsky, Petr $u Cardiocenter, Third Faculty of Medicine, Charles University and University Hospital Kralovske Vinohrady, Prague, Czech Republic
710    2_
$a Prague-18 Study Group
773    0_
$w MED00002299 $t International journal of cardiology $x 1874-1754 $g Roč. 319, č. - (2020), s. 1-6
856    41
$u https://pubmed.ncbi.nlm.nih.gov/32634499 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20210728 $b ABA008
991    __
$a 20210830101429 $b ABA008
999    __
$a ok $b bmc $g 1690603 $s 1140274
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2020 $b 319 $c - $d 1-6 $e 20200704 $i 1874-1754 $m International journal of cardiology $n Int J Cardiol $x MED00002299
LZP    __
$a Pubmed-20210728

Najít záznam

Citační ukazatele

Možnosti archivace